Back to

Michigan

Biologics Compliance Guide for Clinics in Michigan

Learn the essential compliance steps to confidently offer biologics in Alaska. This guide covers state and FDA regulations, patient consent, and best practices to help you establish compliant stem cell therapy services.

1. Summary

This compliance guide provides an accessible roadmap for Michigan clinics and practitioners interested in offering biologics, including stem cell therapies. With essential information on FDA and state regulations, provider qualifications, informed consent, and best practices, this guide is designed to simplify your path to compliance.

2. FDA Compliance

The U.S. Food and Drug Administration (FDA) provides federal guidelines for the regulation of human cells, tissues, and cellular and tissue-based products (HCT/Ps). These regulations help ensure safety, effectiveness, and compliance for therapies such as stem cell treatments.

Clinics must ensure that all biologic treatments comply with FDA’s HCT/P Requirements under 21 CFR Part 1271, as well as any additional federal requirements for investigational or approved therapies.

3. Michigan State Regulations

Michigan requires adherence to both federal biologics guidelines and specific state health regulations. Michigan clinics must review the Michigan Department of Health and Human Services (MDHHS) for guidance on offering biologic treatments.

Although state laws may evolve, following Michigan’s public health regulations for biologics will help ensure that your clinic remains compliant and up-to-date with local legal requirements.

4. Provider Qualifications

In Michigan, licensed healthcare providers such as physicians(MDs/DOs) can administer biologic therapies. IRB approval for clinical trial biologic therapies is required. For detailed licensing information, refer to the Michigan Licensing and Regulatory Affairs (LARA) to confirm you meet the criteria for administering stem cell therapies legally within Michigan.

5. Patient Informed Consent

Informed consent is essential before any biologic therapy. Michigan providers must thoroughly communicate the following to patients:

• Explanation of the treatment, including its experimental nature for certain applications.
• Potential benefits, risks, and side effects of the therapy.
• A clear disclaimer that, in some cases, treatments may lack FDA approval for specific uses.

6. Additional Compliance Practices

To minimize risk and enhance outcomes, Michigan clinics should establish clear pre-treatment and post-treatment protocols, including patient assessment and follow-up care. Regularly updating these protocols according to state and federal guidelines is advised.

Establishing SOPs for all biologic treatments promotes quality and safety in your clinic. Ensure SOPs are documented, accessible to staff, and regularly updated to reflect changes in compliance standards.

Michigan practitioners offering biologics should maintain comprehensive medical liability insurance. Verify that your policy includes coverage for experimental or non-standard treatments as needed.

Marketing of biologics in Michigan must be accurate and avoid misleading claims. Review Michigan advertising guidelines and avoid language suggesting that treatments are "guaranteed" or FDA-approved if they are not.

This guide is provided as an informational resource to help clinics and practitioners understand general compliance requirements for biologics in Michigan. It is not intended to serve as legal advice or replace consultation with qualified legal professionals. Regulations may vary and are subject to change; clinics and practitioners should consult legal counsel or regulatory experts for advice specific to their circumstances and ensure full compliance with all applicable federal and state laws. The authors and publishers of this guide disclaim any liability arising from its use or reliance on the information provided.